MetaVia (MTVA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
The annual meeting will be held virtually on June 8, 2026, with voting available online, by mail, or by proxy.
Five proposals are up for vote: election of two Class I directors, ratification of the auditor, approval of a reverse stock split, amendment to the equity plan, and potential adjournment.
The board unanimously recommends voting in favor of all proposals.
Forward-looking statements highlight risks, uncertainties, and evolving circumstances that may impact future results.
Voting matters and shareholder proposals
Proposal 1: Elect two Class I directors for three-year terms.
Proposal 2: Ratify BDO USA, P.C. as independent auditor for 2026.
Proposal 3: Approve a reverse stock split at a ratio between 1-for-5 and 1-for-22, at board discretion.
Proposal 4: Approve an amendment to the 2022 Equity Incentive Plan to add 200,000 shares.
Proposal 5: Authorize adjournment of the meeting if more votes are needed for Proposals 3 and 4.
Board of directors and corporate governance
The board consists of seven members, with staggered three-year terms.
Board leadership is separated between the Chair and CEO roles.
All directors except the CEO are considered independent under Nasdaq and SEC rules.
Committees include audit, compensation, and nominating/governance, each with defined responsibilities and independent members.
Directors are encouraged to attend annual meetings; all attended in 2025.
Latest events from MetaVia
- Promising dual-action obesity and MASH therapies approach key data and partnership milestones.MTVA
Life Sciences Virtual Investor Forum24 Jun 2026 - DA-1726 and vanoglipol show strong clinical and combination potential, with solid cash runway.MTVA
Emerging Growth Conference 9311 Jun 2026 - All five business proposals, including a reverse stock split, were approved by shareholders.MTVA
AGM 20268 Jun 2026 - Strong clinical pipeline in obesity and MASH targets high-growth markets with near-term catalysts.MTVA
Investor presentation14 May 2026 - Q1 2026 net loss was $3.8M; cash at $13.7M; clinical progress and going concern risk remain.MTVA
Q1 202614 May 2026 - Annual meeting to vote on director elections, reverse split, equity plan, and auditor ratification.MTVA
Proxy filing15 Apr 2026 - Promising obesity and MASH therapies advance with strong early data and major market potential.MTVA
Investor presentation26 Mar 2026 - Strong clinical progress and improved financials position the pipeline for key 2026 milestones.MTVA
Q4 202526 Mar 2026 - DA-1726 and vanoglipel advance in clinical trials, with key data and partnerships expected this year.MTVA
Emerging Growth Virtual Conference25 Feb 2026